Prediction of nasal spray drug absorption influenced by mucociliary clearance.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
09
2020
accepted:
12
01
2021
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
24
6
2021
Statut:
epublish
Résumé
Evaluation of nasal spray drug absorption has been challenging because deposited particles are consistently transported away by mucociliary clearance during diffusing through the mucus layer. This study developed a novel approach combining Computational Fluid Dynamics (CFD) techniques with a 1-D mucus diffusion model to better predict nasal spray drug absorption. This integrated CFD-diffusion approach comprised a preliminary simulation of nasal airflow, spray particle injection, followed by analysis of mucociliary clearance and drug solute diffusion through the mucus layer. The spray particle deposition distribution was validated experimentally and numerically, and the mucus velocity field was validated by comparing with previous studies. Total and regional drug absorption for solute radius in the range of 1 - 110nm were investigated. The total drug absorption contributed by the spray particle deposition was calculated. The absorption contribution from particles that deposited on the anterior region was found to increase significantly as the solute radius became larger (diffusion became slower). This was because the particles were consistently moved out of the anterior region, and the delayed absorption ensured more solute to be absorbed by the posterior regions covered with respiratory epithelium. Future improvements in the spray drug absorption model were discussed. The results of this study are aimed at working towards a CFD-based integrated model for evaluating nasal spray bioequivalence.
Identifiants
pubmed: 33507973
doi: 10.1371/journal.pone.0246007
pii: PONE-D-20-28395
pmc: PMC7842989
doi:
Substances chimiques
Aerosols
0
Nasal Sprays
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246007Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Aerosol Med. 2006 Winter;19(4):510-21
pubmed: 17196079
Respir Physiol Neurobiol. 2012 May 31;181(3):335-45
pubmed: 22465001
Comput Biol Med. 2020 Jan;116:103573
pubmed: 31999554
Comput Biol Med. 2008 Jun;38(6):713-26
pubmed: 18468593
Drug Deliv Transl Res. 2013 Feb;3(1):42-62
pubmed: 23316447
Biophys J. 2001 Oct;81(4):1930-7
pubmed: 11566767
Int J Environ Res Public Health. 2020 Jan 07;17(2):
pubmed: 31935991
J Biomech. 2019 Mar 6;85:74-83
pubmed: 30685195
J Pharm Sci. 2004 Jul;93(7):1725-42
pubmed: 15176062
J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):416-431
pubmed: 26824178
J Aerosol Med. 2006 Fall;19(3):301-13
pubmed: 17034306
Biophys J. 2015 Jul 7;109(1):164-72
pubmed: 26153713
Int J Numer Method Biomed Eng. 2018 Apr;34(4):e2946
pubmed: 29172251
Respir Physiol Neurobiol. 2019 Feb;260:82-94
pubmed: 30445230
Part Fibre Toxicol. 2017 Jul 12;14(1):24
pubmed: 28701167
Allergy Asthma Proc. 2015 Jan-Feb;36(1):48-57
pubmed: 25562556
Pharm Res. 2016 Apr;33(4):909-21
pubmed: 26689412
Biol Pharm Bull. 2015;38(4):497-506
pubmed: 25739664
Respir Physiol Neurobiol. 2014 Jan 1;190:54-61
pubmed: 24051139
Eur J Pharm Sci. 2018 Jun 15;118:113-123
pubmed: 29597042
Toxicol Sci. 2016 Aug;152(2):284-96
pubmed: 27208081
Adv Drug Deliv Rev. 2018 Jan 15;124:16-33
pubmed: 29108861
J Pharm Pharm Sci. 2009;12(3):288-311
pubmed: 20067706
Biorheology. 1987;24(6):557-63
pubmed: 3502756
Adv Drug Deliv Rev. 2005 Nov 3;57(11):1640-65
pubmed: 16182408
Adv Drug Deliv Rev. 2009 Feb 27;61(2):101-14
pubmed: 19135488
Respir Physiol Neurobiol. 2013 Mar 1;186(1):22-32
pubmed: 23313127
J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):139-55
pubmed: 19422314
Comput Biol Med. 2016 Oct 1;77:40-8
pubmed: 27509293